Drug & Device Product Liability Litigation Strategy
Oxford University Press (Verlag)
978-0-19-973494-8 (ISBN)
- Titel ist leider vergriffen;
keine Neuauflage - Artikel merken
Each year, thousands of lawsuits are filed in federal and state courts seeking recovery from manufacturers of pharmaceuticals and medical devices. These lawsuits include individual actions, actions consolidated into multidistrict litigation, and class actions. The litigation occasionally becomes life-threatening for the defendant corporations, and may breed a public relations nightmare, as occurred with Vioxx, breast implants, and fen-phen.
Drug & Device Product Liability Litigation Strategy, by Mark Herrmann and David B. Alden, offers assistance to lawyers who practice in this high-stakes, high-profile, and rapidly-evolving area. The book's primary focus is to provide useful practice pointers and overall strategic guidance for attorneys involved in product liability litigation for prescription drugs and medical devices. It will serve as an indispensable guide to
handling such a case from pre-litigation through trial. The legal landscape in this important area is expected to shift as the Supreme Court's decisions in Riegel v. Medtronic, Inc. and Wyeth v. Levine are applied, and as the President and Congress address tort reform and other health care issues. Practitioners will need thoughtful, expert advice to navigate
these changes.
Mark Herrmann is Vice President and Chief Counsel - Litigation at Aon Corporation, which is the world's leading insurance and reinsurance broker. Before joining Aon, he was a partner at Jones Day, where his practice focused on the defense of class action and mass tort litigation, including pharmaceutical and medical device cases. He clerked for Judge Dorothy W. Nelson of the United States Court of Appeals for the Ninth Circuit and graduated from The University of Michigan Law School (J.D. 1983) and Princeton University (A.B. 1979). David B. Alden is a partner in Jones Day's Cleveland office, where his practice focuses on products liability litigation, including pharmaceutical and medical device cases; securities and accounting fraud litigation; and issues relating to the attorney-client privilege and work product protection.
Acknowledgments ; 1. Introduction ; 2. The FDA's Regulation of Prescription Drugs and Devices ; 3. Pre-litigation Counseling ; 4. Legal Issues & Theories ; 5. Consolidated Proceedings ; 6. Aggregated Proceedings - Class Actions ; 7. Aggregated Proceedings - Multidistrict Litigation ; 8. Fact Discovery ; 9. Expert Retention and Discovery ; 10. Expert Testimony, Rule 702, And Daubert ; 11. Preemption ; 12. The Learned Intermediary Doctrine ; 13. Motions In Limine ; 14. Jury Selection ; 15. The Trial Of A Drug Or Device Case ; Table of Authorities ; Index
| Erscheint lt. Verlag | 1.3.2012 |
|---|---|
| Verlagsort | Oxford |
| Sprache | englisch |
| Maße | 156 x 233 mm |
| Gewicht | 778 g |
| Themenwelt | Recht / Steuern ► EU / Internationales Recht |
| Recht / Steuern ► Privatrecht / Bürgerliches Recht ► Besonderes Schuldrecht | |
| Recht / Steuern ► Privatrecht / Bürgerliches Recht ► Medizinrecht | |
| Recht / Steuern ► Wirtschaftsrecht ► Urheberrecht | |
| ISBN-10 | 0-19-973494-1 / 0199734941 |
| ISBN-13 | 978-0-19-973494-8 / 9780199734948 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
